Skip to main content
. Author manuscript; available in PMC: 2022 Dec 6.
Published in final edited form as: Angew Chem Int Ed Engl. 2021 Nov 5;60(50):26105–26114. doi: 10.1002/anie.202109464

Figure 5. Modification with DC-LC3in-D5 disrupts ATG7-LC3B interaction in HeLa cells and slows down LC3B lipidation in vitro.

Figure 5.

(A) DC-LC3in-D5 blocks ATG7-LC3B interaction in EGFP pull-down assay. (B) In vitro ATG7-LC3B conjugation assay performed with purified proteins and compounds as indicated. The compound:LC3B ratios were 3:1. (C) The quantifications of (B). The ATG7-conjugation ratios of LC3B were calculated in independent experiments (right, ±s.d.; n=3). (D) In vitro LC3B lipidation assay. The concentration of LC3B was 10μM. (E) The quantification of (D). The PE-modification ratio of LC3B was measured in independent lipidation experiments (right, ±s.d.; n=6).